2 Monster Stocks to Hold for the Next 5 Years

Key Points

• These stocks have climbed in the triple digits over the past three years.

• Gains may be far from over as demand for these companies' products soars now and later this decade.

• 10 stocks we like better than Eli Lilly ›

What's a monster stock? In my book, it's a company that's already delivered enormous growth to investors, and considering opportunities ahead, this player should continue to roar higher in the years to come. Today, two stocks in particular fit this description, and they operate in two of the highest growth industries: One is a leader in the weight loss drug market, and the other dominates in the artificial intelligence (AI) market.

The weight loss drug market, from about $28 billion today, is expected to reach $95 billion by the end of the decade, according to Goldman Sachs Research. And analysts forecast the AI market will expand from billions of dollars today to more than $2 trillion in the early 2030s. All of this means these two monster stocks may be heading for a whole new wave of growth -- and that's why they make great stocks to hold for the next five years, or even longer. Let's take a close look at each.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Image source: Getty Images.

1. Eli Lilly

Eli Lilly (NYSE: LLY) has climbed more than 130% over the past three years as customers have flocked to its weight loss drugs. The company commercializes tirzepatide under the name Mounjaro for type 2 diabetes and Zepbound for weight loss -- but doctors have prescribed either for the weight loss indication. Demand has been high, even surpassing supply at times and temporarily landing tirzepatide on the U.S. Food and Drug Administration's drug shortage list.

Tirzepatide is off the shortage list now, but demand remains high and has translated into enormous growth for Lilly. Mounjaro and Zepbound both have become blockbusters, and in the recent quarter, they helped the pharma giant report a 38% increase in revenue to more than $15 billion.

Lilly isn't only a weight loss drug company, of course, and offers a broad portfolio of drugs across therapeutic areas. But the weight loss portfolio could be the driving force behind revenue growth and stock performance in the coming years. And what could offer a new boost is the potential approval of a weight loss drug in pill form (today's drugs are injectables). Lilly recently completed successful clinical trials of oral candidate orforglipron and now is preparing to file for regulatory review.

Lilly's leadership in the weight loss drug market has transformed this pharma company into a monster stock, and both market growth and Lilly's innovation should help it keep up this momentum over the coming years.

2. Taiwan Semiconductor Manufacturing

When you think about AI giants, the first name that may come to mind is AI chip leader, Nvidia. But Nvidia wouldn't be where it is today without another player, a company that makes Nvidia's designs a reality. I'm talking about Taiwan Semiconductor Manufacturing (NYSE: TSM), the manufacturer of Nvidia's chips as well as chips from other market giants such as Advanced Micro Devices and Broadcom.

As a result, TSMC benefits not only from the success of the market leader but also from the successes of many other players. This makes the company a great bet on the high-growth area of AI, especially today as companies increase spending on AI infrastructure -- Meta Platforms and Alphabet made such announcements in their recent earnings calls. TSMC will benefit because those players will rush to Nvidia and other chip designers, and those designers need TSMC to produce their chips.

TSMC has seen revenue advance over time, but it truly took off as the AI boom gathered momentum.

TSM Revenue (Annual) data by YCharts

The chipmaker recently expressed optimism about what's to come, saying demand from companies as well as from countries should continue at a high level. It's also important to keep in mind that Nvidia has pledged to update its chips on an annual basis, this implies more growth ahead for TSMC, the manufacturer of those chips.

Another plus is TSMC is investing $165 billion in U.S. manufacturing, a move that may shield it from the impact of import tariffs and make it easier to work with its U.S. chip customers.

All of this means that investors are likely to benefit if they hold this monster stock -- one that's gained 200% in three years -- as this new phase of AI growth takes off.

Should you invest $1,000 in Eli Lilly right now?

Before you buy stock in Eli Lilly, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $681,260!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,046,676!*

Now, it’s worth noting Stock Advisor’s total average return is 1,066% — a market-crushing outperformance compared to 186% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 8, 2025

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Goldman Sachs Group, Meta Platforms, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy.